168 related articles for article (PubMed ID: 33843254)
1. Costs and health resource use in patients with X-linked myotubular myopathy: insights from US commercial claims.
Sacks NC; Healey BE; Cyr PL; Slocomb T; James E; Beggs AH; Graham RJ
J Manag Care Spec Pharm; 2021 Aug; 27(8):1019-1026. PubMed ID: 33843254
[No Abstract] [Full Text] [Related]
2. Economic and Clinical Burden of Acute Myeloid Leukemia Episodes of Care in the United States: A Retrospective Analysis of a Commercial Payer Database.
Pandya BJ; Chen CC; Medeiros BC; McGuiness CB; Wilson SD; Walsh EH; Wade RL
J Manag Care Spec Pharm; 2020 Jul; 26(7):849-859. PubMed ID: 32281456
[TBL] [Abstract][Full Text] [Related]
3. Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.
Vogelzang NJ; Pal SK; Ghate SR; Li N; Swallow E; Peeples M; Zichlin ML; Meiselbach MK; Perez JR; Agarwal N
J Manag Care Spec Pharm; 2018 Jun; 24(6):525-533. PubMed ID: 29799328
[TBL] [Abstract][Full Text] [Related]
4. Real-world analysis of healthcare resource utilization by patients with X-linked myotubular myopathy (XLMTM) in the United States.
Graham RJ; Darras BT; Haselkorn T; Fisher D; Genetti CA; Miller W; Beggs AH
Orphanet J Rare Dis; 2023 Jun; 18(1):138. PubMed ID: 37280644
[TBL] [Abstract][Full Text] [Related]
5. Health care resource utilization and costs of recurrent
Nelson WW; Scott TA; Boules M; Teigland C; Parente A; Unni S; Feuerstadt P
J Manag Care Spec Pharm; 2021 Jul; 27(7):828-838. PubMed ID: 33703939
[No Abstract] [Full Text] [Related]
6. Economic Burden of Irritable Bowel Syndrome with Diarrhea: Retrospective Analysis of a U.S. Commercially Insured Population.
Buono JL; Mathur K; Averitt AJ; Andrae DA
J Manag Care Spec Pharm; 2017 Apr; 23(4):453-460. PubMed ID: 28345443
[TBL] [Abstract][Full Text] [Related]
7. Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.
Schultz NM; Penson DF; Wilson SD; Song Y; Yang H; Ramaswamy K; Lowentritt B
J Manag Care Spec Pharm; 2019 Aug; 25(8):889-897. PubMed ID: 31172866
[TBL] [Abstract][Full Text] [Related]
8. Health care costs and resource utilization among commercially insured adult patients with hemophilia A managed with FVIII prophylaxis in the United States.
Thornburg CD; Adamski K; Cook K; Vembusubramanian M; Sendhil SR; Hinds D; Chen E; Sammon J; Solari P; Garrison LP; Croteau SE
J Manag Care Spec Pharm; 2022 Apr; 28(4):449-460. PubMed ID: 34958235
[No Abstract] [Full Text] [Related]
9. Health Care Resource Utilization and Exacerbation Rates in Patients with COPD Stratified by Disease Severity in a Commercially Insured Population.
Wallace AE; Kaila S; Bayer V; Shaikh A; Shinde MU; Willey VJ; Napier MB; Singer JR
J Manag Care Spec Pharm; 2019 Feb; 25(2):205-217. PubMed ID: 30698096
[TBL] [Abstract][Full Text] [Related]
10. CME/CNE Article: A Framework of Care in Multiple Sclerosis, Part 1: Updated Disease Classification and Disease-Modifying Therapy Use in Specific Circumstances.
Newsome SD; Aliotta PJ; Bainbridge J; Bennett SE; Cutter G; Fenton K; Lublin F; Northrop D; Rintell D; Walker BD; Weigel M; Zackowski K; Jones DE
Int J MS Care; 2016; 18(6):314-323. PubMed ID: 27999526
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis.
Placzek H; Xu Y; Mu Y; Begelman SM; Fisher M
J Manag Care Spec Pharm; 2015 Dec; 21(12):1106-12. PubMed ID: 26679960
[TBL] [Abstract][Full Text] [Related]
12. Patients with Idiopathic Membranous Nephropathy: A Real-World Clinical and Economic Analysis of U.S. Claims Data.
Nazareth TA; Kariburyo F; Kirkemo A; Xie L; Pavlova-Wolf A; Bartels-Peculis L; Vaidya N; Sim JJ
J Manag Care Spec Pharm; 2019 Sep; 25(9):1011-1020. PubMed ID: 31283419
[TBL] [Abstract][Full Text] [Related]
13. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
[TBL] [Abstract][Full Text] [Related]
14. Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage.
Klimchak AC; Szabo SM; Qian C; Popoff E; Iannaccone S; Gooch KL
J Manag Care Spec Pharm; 2021 Oct; 27(10):1426-1437. PubMed ID: 34595954
[No Abstract] [Full Text] [Related]
15. Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.
Zhdanava M; Kuvadia H; Joshi K; Daly E; Pilon D; Rossi C; Morrison L; Lefebvre P; Nelson C
J Manag Care Spec Pharm; 2020 Aug; 26(8):996-1007. PubMed ID: 32552362
[TBL] [Abstract][Full Text] [Related]
16. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
[TBL] [Abstract][Full Text] [Related]
17. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of erenumab and onabotulinumtoxinA on acute medication usage and health care resource utilization as migraine prevention in the United States.
Tepper SJ; Fang J; Zhou L; Shen Y; Vo P; Abdrabboh A; Glassberg MB; Ferraris M
J Manag Care Spec Pharm; 2021 Sep; 27(9):1157-1170. PubMed ID: 33998825
[No Abstract] [Full Text] [Related]
19. Comparative Assessment of Medical Resource Use and Costs Associated with Patients with Symptomatic Peripheral Artery Disease in the United States.
Chase MR; Friedman HS; Navaratnam P; Heithoff K; Simpson RJ
J Manag Care Spec Pharm; 2016 Jun; 22(6):667-75. PubMed ID: 27231794
[TBL] [Abstract][Full Text] [Related]
20. Increased health care costs associated with new persistent opioid use after major surgery in opioid-naive patients.
Brummett CM; Evans-Shields J; England C; Kong AM; Lew CR; Henriques C; Zimmerman NM; Sun EC
J Manag Care Spec Pharm; 2021 Jun; 27(6):760-771. PubMed ID: 33624534
[No Abstract] [Full Text] [Related]
[Next] [New Search]
